SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending with community chatter focusing on the stock's recent upward momentum, driven by speculation around potential catalysts and technical factors. Some traders point to a possible gamma squeeze and overall market strength, while others express skepticism, citing valuation concerns and mixed fundamentals. The discussion includes debate on whether the rally is sustainable or if a pullback is imminent.

Gemini Space Station Inc. - Ordinary Shares- Class A

Gemini Space Station

Gemini Space Station's IPO is trending amid volatile price action, sparking debates about IPO allocations and the influence of retail investors. The community is weighing the long-term potential against concerns over reported losses and the overall crypto market sentiment, while also comparing it to other recent IPOs. Some traders express excitement about potential gains, while others are wary of the stock's high valuation and the involvement of the Winklevoss twins.

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Atyr Pharma Inc

aTyr Pharma, Inc

Anticipation is building around aTyr Pharma as it approaches the topline Phase 3 data release for efzofitimod in pulmonary sarcoidosis, driving significant community discussion. While some traders are eyeing a potential pump and dump scenario, others are optimistic about the trial's outcome and future indications, highlighting strong institutional ownership and potential for a short squeeze. The community is closely monitoring for any data leaks and debating the influence of prominent figures on the stock's movement.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is trending as the community discusses potential partnerships and integrations, particularly within the Solana ecosystem. Bullish sentiment is fueled by discussions around real-world asset (RWA) adoption and the anticipation of increased volume as more markets open.

Sonnet BioTherapeutics Holdings, Inc. is a clinical stage biotechnology company, which engages in the innovation of biologic medicines. Its Fully Human Albumin Binding (FHAB) technology utilizes a single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its pipeline focuses on cytokines, a class of cell signaling peptides that, among other important functions, serve as potent immunomodulatory agents. The company was founded by Pankaj Mohan and John K. Cini in 2011 and is headquartered in Princeton, NJ.

Sonnet BioTherapeutics Holdings Inc

SONN is trending due to speculation surrounding a potential merger related to cryptocurrency, with community members pointing to a possible short squeeze given the stock's high short interest. Conversations revolve around predictions of a significant price increase and the potential impact of the merger on shareholder value. Some traders are actively shorting the stock, anticipating a price crash, while others remain bullish, drawing comparisons to similar stocks that have experienced substantial gains.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer ($PFE) is trending due to reports suggesting the Trump administration may link COVID-19 vaccines to child deaths, sparking concerns about potential liabilities and renewed scrutiny of vaccine safety data. The community is debating the validity of the reports and the potential impact on vaccine manufacturers, while some investors see the dip as a buying opportunity for the high-dividend stock.  Others believe Pfizer is more than just a vaccine company and should be evaluated as a cancer treatment company.

Asset Entities, Inc. engages in providing social media marketing and content delivery services. It offers its services to Discord, TikTok, and other social media platforms. It also designs, develops and manages servers for communities on Discord. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani and Kyle Fairbanks on August 1, 2020 and is headquartered in Dallas, TX.

Asset Entities Inc - Ordinary Shares - Class B

Asset Entities Inc.

Asset Entities Inc. is trending as traders anticipate the closing of its merger with Strive, potentially transforming it into a Bitcoin treasury company; high short interest and borrow fees add to the excitement, with the community debating the impact of potential dilution and the timing of news releases, as well as the possibility of a short squeeze. Despite some volatility, many investors express confidence in the long-term potential, urging others to hold firm.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FCEL is trending due to recent earnings and increased discussion around its potential in AI data center power, with community members highlighting its fast “contract-to-power” deployment. Some are expressing optimism for a continued rally, while others are debating the company's path to profitability and comparing it to sector peers like BE and PLUG. Discussion also includes potential catalysts such as new deals, partnerships, and broader adoption of clean energy initiatives.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

Cleanspark is trending as investors discuss its potential pivot towards HPC/AI, with some expressing frustration over the stock's recent performance compared to other miners like CIFR and IREN. Community members are debating whether the company is undervalued, with several pointing to its Bitcoin holdings and infrastructure, while others express concerns about management and past decisions. Some traders anticipate a potential breakout, while others discuss short positions and technical indicators.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending due to regulatory clearance for its acquisition of Oxford Ionics, sparking discussions about the company's future and potential catalysts such as the upcoming Quantum World Congress. Community perspectives are mixed, with some highlighting the acquisition's significance while others express concerns about revenue and valuation. The stock is also being compared to NVDA, with some seeing it as the next big thing in computing.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates

Rhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of -13.64% and +11.73%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Exact Sciences (EXAS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q2 Earnings Expected to Decline

Rhythm Pharmaceuticals (RYTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Investing.com’s stocks of the week

Investing.com -- Markets concluded the week with a notable shift in sentiment. After reaching record highs earlier, U.S. stocks closed lower on Friday, impacted by macroeconomic concerns.

RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data

Rhythm Pharmaceuticals jumps 36.6% after its oral drug bivamelagon shows strong BMI and hunger reductions in a phase II study in acquired hypothalamic obesity.

Rhythm Pharmaceuticals received a wave of price target hikes on Wednesday after releasing&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rhythm-pharma-experimental-drug-yields-weight-reduction-in-brain-damage-related-obesity/chFy2A1R5KT">encouraging Phase 2 results</a> for bivamelagon, its experimental oral treatment for hypothalamic obesity.LeerinkLeerink bumped its target to $102 from $88, keeping an 'Outperform' rating on the stock.&nbsp;The firm updated its estimates following the company's disclosure of Phase 2 data for bivamelagon, which it described as “close to a best-case scenario.”&nbsp;Leerink said investor feedback has been highly positive regarding efficacy, with minimal concerns on safety.NeedhamNeedham increased its price target to $95 from $72 and kept a 'Buy' rating.&nbsp;The firm raised its probability of success (PoS) for the bivamelagon program to 70% from 40% based on the Phase 2 results and lowered its discount rate in its discounted cash flow (DCF) model to 8% from 9.5% to reflect reduced overall risk.&nbsp;Needham added that, aside from some manageable exceptions, the tolerability profile for bivamelagon looks better than&nbsp;that of setmelanotide.Morgan Stanley&nbsp;Morgan Stanley lifted its price target to $95 from $80 and maintained an 'Overweight' rating.&nbsp;The firm noted that the Phase 2 data indicated BMI reductions above the 10% threshold, in the range of setmelanotide, with an improved profile.&nbsp;Morgan Stanley stated that this supports the advancement of bivamelagon into Phase 3 trials, which are expected in the first half of 2026.&nbsp;The firm also said early data confirm the potential for bivamelagon to expand or extend Rhythm’s opportunity in hypothalamic obesity.BofABofA raised its price target to $95 from $73 and kept a 'Buy' rating.&nbsp;The firm cited the positive topline results for bivamelagon and said the data suggest an efficacy profile similar to setmelanotide, but with more convenient once-daily oral dosing.StifelStifel raised its target to $123 from $94 and maintained a 'Buy' rating.&nbsp;The firm cited the Phase 2 data for bivamelagon and stated the treatment is now “derisked” on efficacy and “mostly derisked” on safety.&nbsp;Stifel said Rhythm now has an opportunity to extend the duration of its MC4R franchise beyond 2040.Wells FargoWells Fargo increased its price target to $129 from $91 and kept an 'Overweight' rating.&nbsp;The firm said the Phase 2 data are a “key inflection” for Rhythm’s MC4R franchise and that the stock should “trade up meaningfully.”&nbsp;Wells estimates the data adds approximately $35 per share in value and significantly increases the probability of success and durability for Rhythm’s MC4R franchise into the mid-2040s.On Stocktwits, retail sentiment for Rhythm was ‘extremely bullish’ amid ‘extremely high’ message volume.<a href="https://stocktwits.com/symbol/RYTM">Rhythm’s stock</a> has risen 48.2% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Analysts from Wells Fargo, Stifel, and others raised their targets on Rhythm Pharma (RYTM) following the release of strong BMI reduction data for bivamelagon/ Photo credit: Getty Images

Rhythm Pharma Gets Price-Target Bump Ups To $129 After Oral Obesity Drug Impresses In Phase 2; Retail Appetite Swells

Rhythm Pharmaceuticals received a wave of price target hikes on Wednesday after releasing encouraging Phase 2 results for bivamelagon, its experimental oral treatment for hypothalamic obesity.

Equity

Analysts from Wells Fargo, Stifel, and others raised their targets following the release of strong BMI reduction data for bivamelagon.

Rhythm Pharmaceuticals, Inc. (RYTM) on Wednesday announced that its drug Bivamelagon achieved statistically significant and clinically meaningful reductions in body mass index (BMI) in patients with acquired hypothalamic obesity in a mid-stage trial.<a href="https://stocktwits.com/symbol/RYTM">Rhythm’s shares</a> were trading 31% higher at the time of writing.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.rhythmtx.com/news-releases/news-release-details/rhythm-pharmaceuticals-announces-oral-mc4r-agonist-bivamelagon">said</a> that Bivamelagon achieved as much as a 9.3% reduction from baseline in body mass index at 14 weeks of treatment. Patients also reported meaningful reduction in their ‘most’ hunger scores at 14 weeks on therapy as compared to placebo, the company said.CEO David Meeker said that the company is excited by the results, which suggest Bivamelagon has the potential to treat patients with acquired hypothalamic obesity. Rhythm in-licensed Bivamelagon from LG Chem, Ltd in January 2024.Acquired hypothalamic obesity is a rare form of obesity that occurs following damage to the hypothalamic region of the brain, which most frequently follows the growth or surgical removal of craniopharyngioma, astrocytoma, or other rare brain tumors.Patients experience accelerated weight gain, a reduction in energy expenditure, and hyperphagia (a chronic pathological condition characterized by insatiable hunger, impaired satiety, and persistent abnormal food-seeking behaviors), leading to severe obesity within six to 12 months following tumor resection or other injury.Rhythm now plans to seek input from U.S. and EU regulatory authorities on a late-stage trial design to advance Bivamelagon in acquired hypothalamic obesity. The company is also refining the formulation of Bivamelagon, potentially to improve tolerability ahead of initiating a late-stage trial, as one of the 28 patients in the mid-stage study discontinued therapy due to rectal bleeding.Rhythm estimates there are 5,000 to 10,000 people living with hypothalamic obesity in the U.S., 5,000 to 8,000 people living with hypothalamic obesity in Japan, and 3,500 to 10,000 people living with hypothalamic obesity in the E.U.On Stocktwits, retail sentiment around RYTM jumped from ‘bullish’ to ‘extremely bullish’ over the past 24 hours while message volume jumped from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:623/67;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_09_at_11_39_04_AM_png_f718a4e952.webp" alt="RYTM's Sentiment Meter and Message Volume as of 11:39 a.m. ET on July 9, 2025 | Source: Stocktwits" width="623" height="67"><figcaption>RYTM's Sentiment Meter and Message Volume as of 11:39 a.m. ET on July 9, 2025 | Source: Stocktwits</figcaption></figure>RYTM stock is up by about 52% this year and by about 90% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/trump-slaps-30-tariff-on-iraq-says-its-less-than-what-is-needed/chFy2f8R5Kb">Trump Slaps 30% Tariff On Iraq, Says It’s ‘Less Than What Is Needed’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Rhythm Pharmaceuticals company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Rhythm Pharma Shares Soar After Experimental Drug Yields Weight Reduction In Brain-Damage Related Obesity

Rhythm now plans to seek input from U.S. and EU regulatory authorities on a late-stage trial design to advance Bivamelagon in acquired hypothalamic obesity.

Shares of Rhythm Pharmaceuticals Inc. (RYTM) traded 14% higher on Monday noon after the company<a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.rhythmtx.com/news-releases/news-release-details/rhythm-pharmaceuticals-announces-pivotal-phase-3-transcend-trial"> announced</a> positive results from a trial of setmelanotide therapy in the treatment of acquired hypothalamic obesity and subsequent price target upgrades.The biopharmaceutical company announced positive results from its phase 3 trial evaluating setmelanotide, a melanocortin-4 receptor (MC4R) agonist, for treating acquired hypothalamic obesity.Acquired hypothalamic setmelanotide is a rare form of obesity resulting from damage to the hypothalamus, resulting in accelerated weight gain and insatiable hunger.The company estimates there are 5,000 to 10,000 people living with hypothalamic obesity in the U.S.The company said that it observed a statistically significant and highly clinically meaningful reduction in body mass index (BMI) with setmelanotide in both adult and pediatric patients as compared to those administered with a placebo.CEO David Meeker said that the company is preparing to submit a supplemental New Drug Application to the FDA and a Type II variation request to the European Medicines Agency in the third quarter of 2025.Bank of America subsequently upgraded the pharmaceutical company’s rating to ‘Buy’ from ‘Neutral’ while also hiking the price target to $63, up from $60.BofA opined that the company’s setmelanotide is "likely approvable" based on recent data provided by the company.The recent pullback in the shares offers "additional upside opportunity", the analyst told investors, according to TheFly.Wells Fargo also raised its price target on the company to $91 from $80 while keeping an “Overweight” rating on the shares.The firm, which believes that the shares should be trading higher on the trial data, said that the trial results are “solid” and near the bull case.Wells sees Rhythm trading to over $100 per share by the end of 2025.On Stocktwits, retail sentiment about RYTM jumped higher in the ‘extremely bullish’ territory while message volume rose from ‘high’ to ‘extremely high’ levels over the past 24 hours.<figure class="image"><img style="aspect-ratio:1302/294;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_07_at_2_11_21_PM_png_23de55ab36.webp" alt="RYTM's Sentiment Meter and Message Volume as of 2:10 p.m. ET on April 7, 2025 | Source: Stocktwits" width="1302" height="294"><figcaption>RYTM's Sentiment Meter and Message Volume as of 2:10 p.m. ET on April 7, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/RYTM">RYTM shares</a> are down by over 11% this year but up by nearly 28% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/trump-threatens-china-with-50-additional-tariffs/chf1CZ6Rb7r">Trump Threatens China With 50% Additional Tariffs If Xi Jinping’s Administration Fails To Lift Duties By Tuesday, Warns Termination Of Talks</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Rhythm Pharmaceuticals Stock Rises On Positive Trial Data From Therapy In Treating Hypothalamic Obesity: Retail, Analysts Get More Bullish 

CEO David Meeker said the company is preparing to submit a supplemental New Drug Application to the FDA and a Type II variation request to the European Medicines Agency in the third quarter of 2025. 

Eli Lilly, Roku among others added to Wells Fargo's tactical ideas list

Investing.com -- Wells Fargo has released its Q2 2025 Tactical Ideas list on Tuesday, highlighting 10 stocks across nine subsectors that analysts believe could see significant catalysts in the coming quarter. 

A Glimpse Into The Expert Outlook On Rhythm Pharmaceuticals Through 4 Analysts

Latest Ratings for RYTM
 DateFirmActionFromTo Mar 2022Canaccord GenuityMaintainsBuy Mar 2022NeedhamMaintainsBuy Feb 2022NeedhamMaintainsBuy
 View More Analyst Ratings for RYTM

 View the...

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.

Current Price	$96.32
Prev Close	$97.92
Open	$97.74
Dividend Yield	0.00%
50-Day Moving Average	$92.07
Beta	1.24
Avg. Volume	576,540.86
PE Ratio	-32.44

52-Week High	$106.52
52-Week Low	$45.91
Market Capitalization	$6.5B
EPS (Annual)	-$4.34
Price to Book	-525.55
Revenue Per Employee	$459,809.19
Enterprise Value/EBITDA	N/A

RYTM
Rhythm Pharmaceuticals Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RYTM News

RYTM Rhythm Pharmaceuticals Inc.